- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Linezolid 600 mg.
Displaying page 1 of 3.
EudraCT Number: 2020-005772-35 | Sponsor Protocol Number: LINEZOLID01 | Start Date*: 2021-04-21 |
Sponsor Name:UCLouvain | ||
Full Title: Study on linezolid use and adverse drug reactions in clinical practice: Follow-up of patients treated in Belgian Hospitals | ||
Medical condition: All infections treated with the antibiotic linezolid | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005127-33 | Sponsor Protocol Number: UGENT_LIMOP | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:University Ghent | |||||||||||||
Full Title: Pharmacokinetic and pharmacodynamic evaluation of linezolid administered intravenously in MRSA-positive, morbidly obese patients with pneumonia. | |||||||||||||
Medical condition: MRSA-positive, morbidly obese patients with pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000899-16 | Sponsor Protocol Number: UMM022013TG | Start Date*: 2013-10-16 |
Sponsor Name:Department of Pharmacy Unversitätsmedizin Mainz | ||
Full Title: Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy | ||
Medical condition: Sepsis and acute renal failure (ARF) are pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated and ma... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004886-98 | Sponsor Protocol Number: TOC110978 | Start Date*: 2017-01-24 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily... | |||||||||||||
Medical condition: secondarily-infected traumatic lesions (SITL; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000158-47 | Sponsor Protocol Number: J&P002/2011 | Start Date*: 2012-01-19 |
Sponsor Name:Klin. Abtlg. für Thorax- & Hyperbare Chirurgi | ||
Full Title: Assessment of extracellular concentrations of linezolid and other currently approved antibiotics in patients presenting with severe bacterial lung infection | ||
Medical condition: Subjects who are scheduled to undergo elective open-chest lung surgery will be included in the study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004154-22 | Sponsor Protocol Number: TR701-132 | Start Date*: 2014-04-17 | |||||||||||
Sponsor Name:Trius Therapeutics, a Wholly Owned Subsidiary of Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Double-blind Study Comparing TR 701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia | |||||||||||||
Medical condition: Ventilated Gram-positive nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) GR (Completed) SK (Completed) CZ (Completed) EE (Completed) GB (Completed) HR (Completed) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006153-41 | Sponsor Protocol Number: J&P004/2008 | Start Date*: 2009-03-30 |
Sponsor Name:Medical university Graz, Department of Plastic Surgery | ||
Full Title: Target site pharmacokinetics of linezolid after repetitive doses in diabetic patients with bacterial foot infection | ||
Medical condition: The study population will consist of a representative group of adult male or female patients with documented diabetes and bacterial soft tissue infection of the foot complicated by osteomyelitis. P... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002303-14 | Sponsor Protocol Number: A5951110 | Start Date*: 2008-12-17 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA | |||||||||||||
Full Title: PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER | |||||||||||||
Medical condition: This study is designed to understand the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for two months or longer for the developmen... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001200-12 | Sponsor Protocol Number: A5951002 | Start Date*: 2007-08-27 | |||||||||||
Sponsor Name:Pfizer Global Research and Development | |||||||||||||
Full Title: Linezolid In The Treatment Of Complicated Skin And Soft Tissue Infections Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus | |||||||||||||
Medical condition: Complicated skin and soft tissue infections | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002683-32 | Sponsor Protocol Number: DUR001-305 | Start Date*: 2015-03-30 | |||||||||||
Sponsor Name:Durata Therapeutics International B.V. | |||||||||||||
Full Title: A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia | |||||||||||||
Medical condition: Community acquired bacterial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001082-17 | Sponsor Protocol Number: DELA-01 | Start Date*: 2019-08-19 | |||||||||||
Sponsor Name:MENARINI RICERCHE S.p.A. | |||||||||||||
Full Title: A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched populatio... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) SI (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002278-33 | Sponsor Protocol Number: PK_AB_NICU | Start Date*: 2018-09-27 |
Sponsor Name:Department of Clinical Pharmacology/Medical University of Vienna | ||
Full Title: Pharmacokinetics of antibiotics in cerebrospinal fluid of children with external ventricular drain | ||
Medical condition: We will obtain pharmacokinetic data of cefuroxime, vancomycin, gentamicin, ampicillin, linezolid, piperacillin/tazobactam and cefazolin in cerebrospinal fluid and plasma of children with external v... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003644-23 | Sponsor Protocol Number: PTK0796-ABSI-1108 | Start Date*: 2015-07-02 | |||||||||||
Sponsor Name:Paratek Pharma LLC | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Str... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) ES (Completed) PL (Completed) GR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000781-38 | Sponsor Protocol Number: PHAO2011/LB/LIZ-BONE | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Direction de la recherche clinique du centre hospitalier universitaire de Tours, Bretonneau | |||||||||||||
Full Title: Prospective, Randomized, open label, European, multicenter study of the efficacy of the linezolid-rifampin combination versus standard of care in the treatment of Gram-positive prosthetic hip joint... | |||||||||||||
Medical condition: Hip prosthesis infected by gram-positive bacteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001730-17 | Sponsor Protocol Number: BAP00248/307 | Start Date*: 2004-09-16 | |||||||||||
Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: A Phase 3, Randomized Double-Blind Study of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia | |||||||||||||
Medical condition: Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) HU (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005159-32 | Sponsor Protocol Number: A5951105 | Start Date*: 2005-04-28 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: Linezolid vs Vancomycin/Cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections | |||||||||||||
Medical condition: Catheter-related Gram-positive bloodstream infections. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000513-39 | Sponsor Protocol Number: LIN-interaction-01 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients | |||||||||||||
Medical condition: Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024042-30 | Sponsor Protocol Number: DUR001-301 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Durata Therapeutics, Inc | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKI... | |||||||||||||
Medical condition: acute bacterial skin and skin structure infections (abSSSI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004947-65 | Sponsor Protocol Number: IMPACT-TDM | Start Date*: 2021-05-17 | |||||||||||||||||||||
Sponsor Name:Santiago Grau Cerrato | |||||||||||||||||||||||
Full Title: IMPACT ON THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF THE ANTIMICROBIAL THERAPEUTIC MONITORING PROGRAM IN CRITICAL PATIENTS | |||||||||||||||||||||||
Medical condition: - Respiratory infections - Urogenital infections - Abdominal infections | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002860-26 | Sponsor Protocol Number: TR701-113 | Start Date*: 2011-12-21 | |||||||||||
Sponsor Name:Trius Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10-Day Linezolid for the Treatment of... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
